EuroPharma Today

Fireside Chat With Sanofi Aventis CSO Laurence Debroux

Laurence Debroux covers all Sanofi-Aventis’ business development and acquisition activities as well as corporate planning, financial and economic evaluation of internal and external projects, and strategic intelligence. 

Top Pharma Dealmakers To Gather in Paris

Are you looking to grow your biopharma business through financing, M&A or stratgic partnerships?

Top Medical Technology Dealmakers Gather In Paris

Are you looking to grow your medical technology business through financing, M&A or strategic partnerships? At IN3 Europe (April 28-30, Paris), medical technology innovators have the opportunity to meet the top investors, VCs and business development executives - all in a single forum.

Season's Greetings (Oh Yes, And A Gift Too!)

We wish all our readers a joyful holiday season and all the best for 2010. EuroPharma Today will resume publishing in the new year. As a small token of thanks for your support this year, we'd like to offer you a complimentary issue of IN VIVO!

A Baker's Dozen: The Top EuroPharma Today Stories Of 2009

It's end-of-the-year time again, and like a lot of publications, EuroPharma Today is taking stock of 2009 - remembering which stories were naughty, and which were nice - and planning ahead for New Year's resolutions in 2010.

Public Interest/Private Sector: Collaboration and Conflict in Drug Development?

This complimentary webinar (Dec. 15, 6 pm CET) brings together thought leaders for a candid discussion of the implications of different approaches to managing industry/academic relationships on the enterprise of drug development.

Looking For Creative Strategies To Optimize Your Drug's Positioning & Reimbursement?

During this November 24 webinar, you’ll learn just what kinds of novel, brand-boosting payor deals pharma firms are creating. 

Medical Device Market 2009: Interventional Cardiology

Elsevier Business Intelligence announces the publication of a new Special Report: Medical Device Market 2009 Interventional Cardiology. Who’s going beyond catheters and drug-eluting stents in this vibrant space. A special report previously published in IN VIVO: The Business & Medicine Report™  Read more...

Special report on REMS: Industry’s Newest Fast-Track to Approval

FDA’s REMS Program: How It Can Hurt – or HELP – your Drug
Guidance for a smooth approval process & working successfully with the new requirements

FDA's new power to require Risk Evaluation and Mitigation Strategies (REMS) as part of a drug’s approval could be the most important change to FDA’s authority in the last 20 years. The questions for drug sponsors are abundant: How often are REMS provisions required for new drugs? What could trigger a REMS requirement for my drug? What types of REMS provisions are typically required? At what stage of drug development should I start planning for REMS? Will my drug be delayed while I negotiate REMS requirements with FDA? Are there any commercial opportunities I can turn to my advantage from having a REMS?

In this Special Report, you get answers to all these questions and many more, from our analysis of the most important REMS programs to date, to the specific regulatory and commercial experiences of the first companies to go through the REMS process.

This detailed 43-page report includes critical information for regulatory, legal, R&D, and business development executives, and anyone who works for or with biopharma companies to meet the new REMS requirements. Get this exclusive report now! Follow this link for details.

Top China Health Reform Insider To Speak At PharmAsia Summit In San Francisco

Dear Colleague:

In the last year, I have had the good fortune to visit with Song Ruilin several times during my travels to China. Professor Song is the Executive Director-General of the China Pharmaceutical Association's Research Center for Medicinal Policy and Chairman of the Chinese Journal of New Drugs. He is among the most influential figures in China healthcare reform and pharmaceutical policy. He rarely speaks publicly and seldom visits the U.S.